



Miami Jewish Health Systems®

Clinical Research Trials

Name of Study: Accera - AC-12-010

Description of Study: A nourish trial, powered formulation as a (medical food beverage) compared to placebo for the safety, efficacy, and quality of life in individuals with mild or moderate Alzheimer's disease.

Recruiting Subjects Ages: 66-90

Duration of Study: 26 weeks

Name of Study: Chase CPC-001-07

Description of Study: A study to evaluate safety and tolerability of the approved medication Donepezil administered at higher doses in parallel with Solifenacin in-patient with Alzheimer's disease.

Recruiting Subjects Ages: 50 - 79

Duration of Study: up to 6 Months

Name of Study: Eisai – BAN2401-G000-201

Description of Study: (Phase 2) an anti-amyloid monoclonal antibody administered through Intravenous infusion treatments every 2 weeks compared to placebo in subjects with mild cognitive impairment due to Alzheimer's disease or mild Alzheimer's disease.

Recruiting Subjects Ages: 50-90

Duration of Study: 18 month

Name of Study: EnVivo EVP-6124

Description of Study: Study to evaluate the safety and efficacy of an oral medication compared with placebo in subjects with mild to moderate Alzheimer's disease.

Recruiting Subjects Ages: 55-85

Duration of Study: 26 weeks

Name of Study: Genentech GN29632

Description of Study: Study to evaluate that Crenezumab administered as an intravenous infusion every 4 weeks compared to placebo will slow the cognitive and functional decline of Alzheimer's disease in patients with mild to moderate Alzheimer's disease.

Recruiting Subjects Ages: 50 - 90

Duration of Study: up to 7 Months

Name of Study: Lunbeck 14862A

Description of Study: A study to evaluate the efficacy of an oral medication compared to placebo in-patient with mild-moderate Alzheimer's disease with donepezil.

Recruiting Subjects Ages: 50 or older

Duration of Study: 7 Months

Name of Study: Merck 019-00

Description of Study: A phase III study to investigate the safety and efficacy of an oral medication compare with placebo in participants with amnesic Mild Cognitive Impairment.

Recruiting Subjects Ages: 50 to 85

Duration of Study: 26 Months

Name of Study: Neuronix NRX-US4

Description of Study: The NeuroAD system is a combined system of Transcranial Magnetic Stimulation and cognitive training and is a non-invasive therapeutic system for the improvement of Alzheimer patients' cognitive function.

Recruiting Subjects Ages: 60 to 90

Duration of Study: 18-24 Months

Name of Study: Otsuka 331-12-283

Description of Study: Study to evaluate the efficacy of 3 fixed doses of Brexpiprazole in the treatment of subjects with agitations associated with Alzheimer's disease.

Recruiting Subjects Ages: 55 to 90

Duration of Study: 12 Week

Name of Study: Roche WN28745

Description of Study: A Study to evaluate the efficacy and safety of Gantenerumab compared to placebo in-patient with mild Alzheimer's disease.

Recruiting Subjects Ages: 50 to 90

Duration of Study: 43 Months

If you're interested in participating in a clinical research trial, please call the research hotline at 305.514.8710.